Gender and cataract-The role of estrogen

Current Eye Research

Volumn 40, Issue 2, 2015, Pages 176-190

  Zetterberg, Madeleine ^a   Celojevic, Dragana ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Aging; Cataract; Epidemiology; Estrogen; Estrogen receptors; Gender; Lens epithelial cells; Oxidative stress

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1;

CATARACT; CATARACT EXTRACTION; CATARACTOGENESIS; CELL CULTURE; ENZYME PHOSPHORYLATION; ESTROGEN BLOOD LEVEL; GENDER; HORMONAL THERAPY; HUMAN; INCIDENCE; LENS; LENS EPITHELIUM; LENS EPITHELIUM CELL; LIFE EXPECTANCY; LIFESPAN; LIFESTYLE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TELOMERE; AGING; EPITHELIUM CELL; FEMALE; MALE; METABOLISM; PHYSIOLOGY;

AGING; CATARACT; EPITHELIAL CELLS; ESTROGENS; FEMALE; HUMANS; LENS, CRYSTALLINE; MALE; OXIDATIVE STRESS; RECEPTORS, ESTROGEN; SEX FACTORS;

EID: 84921674750     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.898774     Document Type: Review

References (162)

1. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population: The Beaver Dam Eye Study. Ophthalmology 1992;99:546-552.
2. Leske MC, Connell AM, Wu SY, Hyman L, Schachat A. Prevalence of lens opacities in the Barbados Eye Study. Arch Ophthalmol 1997;115:105-111.
3. Mitchell P, Cumming RG, Attebo K, Panchapakesan J. Prevalence of cataract in Australia: The Blue Mountains eye study. Ophthalmology 1997;104:581-588.
4. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012;96:614-618.
5. Klein BE, Klein R, Linton KL, Magli YL, Neider MW. Assessment of cataracts from photographs in the Beaver Dam Eye Study. Ophthalmology 1990;97:1428-1433.
6. Chew EY, Kim J, Sperduto RD, Datiles 3rd MB, Coleman HR, Thompson DJ, et al. Evaluation of the agerelated eye disease study clinical lens grading system AREDS report No.31. Ophthalmology 2010;117:2112-2119.
7. Chylack Jr LT, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol 1993;111:831-836.
8. Hall AB, Thompson JR, Deane JS, Rosenthal AR. LOCS III versus the Oxford Clinical Cataract Classification and Grading System for the assessment of nuclear, cortical and posterior subcapsular cataract. Ophthalmic Epidemiol 1997;4:179-194.
9. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, et al. The Framingham Eye Study. I. Outline and major prevalence findings. Am J Epidemiol 1977; 106:17-32.
10. Carlsson B, Sjostrand J. Increased incidence of cataract extractions in women above 70 years of age. A population based study. Acta Ophthalmol Scand 1996;74:64-68.
11. Lundstrom M, Stenevi U, Thorburn W. Gender and cataract surgery in Sweden 1992-1997. A retrospective observational study based on the Swedish National Cataract Register. Acta Ophthalmol Scand 1999;77:204-208.
12. Ostberg A, Loth A, Gustafson D, Lindblom B. Skovde cataract study: I. Prevalence of lens opacities in a Swedish community. Ophthalmology 2006;113:970-975.
13. Zhang JS, Xu L, Wang YX, You QS, Wang JD, Jonas JB. Five-year incidence of age-related cataract and cataract surgery in the adult population of greater Beijing: The Beijing Eye Study. Ophthalmology 2011;118:711-718.
14. Klein BEK, Klein R, Linton KLP. Prevalence of age-related lens opacities in a population. Ophthalmology 1992;99: 546-552.
15. Gollogly HE, Hodge DO, St Sauver JL, Erie JC. Increasing incidence of cataract surgery: Population-based study. J Cataract Refract Surg 2013;39:1383-1389.
16. Klein BE, Klein R, Lee KE. Incidence of age-related cataract over a 10-year interval: The Beaver Dam Eye Study. Ophthalmology 2002;109:2052-2057.
17. Koo E, Chang JR, Agron E, Clemons TE, Sperduto RD, Ferris 3rd FL, et al.Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. Ophthalmic Epidemiol 2013;20:71-81.
18. Lundstrom M, Barry P, Henry Y, Rosen P, Stenevi U. Participation in the EUREQUO database report. J Cataract Refract Surg 2012;38:1510.
19. Lundstrom M, Stenevi U, Thorburn W. The Swedish National Cataract Register: A 9-year review. Acta Ophthalmol Scand 2002;80:248-257.
20. Olofsson P, Lundstrom M, Stenevi U. Gender and referral to cataract surgery in Sweden. Acta Ophthalmol Scand 2001;79:350-353.
21. Monestam E, Wachtmeister L. Cataract surgery from a gender perspective-A population based study in Sweden. Acta Ophthalmol Scand 1998;76:711-716.
22. Smirthwaite G, Lundstrom M, Albrecht S, Swahnberg K. Indication criteria for cataract extraction and gender differences in waiting time. Acta Ophthalmol 2013 [Epub ahead of print].
23. Lewallen S, Courtright P. Gender and use of cataract surgical services in developing countries. Bulletin of the World Health Organization 2002;80:300-303.
24. Abou-Gareeb I, Lewallen S, Bassett K, Courtright P. Gender and blindness: A meta-analysis of population-based prevalence surveys. Ophthalmic Epidemiol 2001;8:39-56.
25. Lewallen S, Mousa A, Bassett K, Courtright P. Cataract surgical coverage remains lower in women. Br J Ophthalmol 2009;93:295-298.
26. Chang JR, Koo E, Agron E, Hallak J, Clemons T, Azar D, et al. Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology 2011; 118:2113-2119.
27. Leske MC, Wu SY, Nemesure B, Yang L, Hennis A. Nineyear incidence of lens opacities in the Barbados Eye Studies. Ophthalmology 2004;111:483-490.
28. McCarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol 1999;128:446-465.
29. Hennis A, Wu SY, Nemesure B, Leske MC. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch Ophthalmol 2004;122: 525-530.
30. Storey P, Munoz B, Friedman D, West S. Racial differences in lens opacity incidence and progression: The Salisbury Eye Evaluation (SEE) study. Invest Ophthalmol Vis Sci 2013;54:3010-3018.
31. Richter GM, Torres M, Choudhury F, Azen SP, Varma R. Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: The Los Angeles Latino Eye Study. Ophthalmology 2012;119:547-554.
32. Hiller R, Sperduto RD, Ederer F. Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 1986;124:916-925.
33. Hollows F, Moran D. Cataract-the ultraviolet risk factor. Lancet 1981;2:1249-1250.
34. Taylor HR, West SK, Rosenthal FS, Munoz B, Newland HS, Abbey H, et al. Effect of ultraviolet radiation on cataract formation. N Engl J Med 1988;319:1429-1433.
35. Sasaki H, Kawakami Y, Ono M, Jonasson F, Shui YB, Cheng HM, et al. Localization of cortical cataract in subjects of diverse races and latitude. Invest Ophthalmol Vis Sci 2003;44:4210-4214.
36. Schein OD, West S, Munoz B, Vitale S, Maguire M, Taylor HR, et al. Cortical lenticular opacification: Distribution and location in a longitudinal study. Invest Ophthalmol Vis Sci 1994;35:363-366.
37. Duquia RP, Menezes AM, Almeida Jr HL, Reichert FF, Santos Ida S, Haack RL, et al. Prevalence of sun exposure and its associated factors in southern Brazil: A populationbased study. Anais brasileiros de dermatologia 2013;88: 554-561.
38. Klein BE, Cruickshanks KJ, Klein R. Leisure time, sunlight exposure and cataracts. Documenta ophthalmologica. Advances in ophthalmology 1994;88:295-305.
39. Glanz K, Buller DB, Saraiya M. Reducing ultraviolet radiation exposure among outdoor workers: State of the evidence and recommendations. Environ Health: Global Access Sci Source 2007;6:22.
40. Risk factors associated with age-related nuclear and cortical cataract: A case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. Ophthalmology 2001;108:1400-1408.
41. Delcourt C, Cristol JP, Tessier F, Leger CL, Michel F, Papoz L. Risk factors for cortical, nuclear, and posterior subcapsular cataracts: The POLA study. Pathologies Oculaires Liees a l'Age. Am J Epidemiol 2000;151:497-504.
42. Klein BE, Klein R, Lee KE, Meuer SM. Socioeconomic and lifestyle factors and the 10-year incidence of age-related cataracts. Am J Ophthalmol 2003;136: 506-512.
43. Lindblad BE, Hakansson N, Svensson H, Philipson B, Wolk A. Intensity of smoking and smoking cessation in relation to risk of cataract extraction: A prospective study of women. Am J Epidemiol 2005;162:73-79.
44. Chylack Jr LT, Brown NP, Bron A, Hurst M, Kopcke W, Thien U, et al. The Roche European American Cataract Trial (REACT): A randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol 2002;9:49-80.
45. Taylor A, Jacques PF, Chylack Jr LT, Hankinson SE, Khu PM, Rogers G, et al. Long-term intake of vitamins and carotenoids and odds of early age-related cortical and posterior subcapsular lens opacities. Am J Clin Nutr 2002; 75:540-549.
46. Jacques PF, Chylack Jr LT, Hankinson SE, Khu PM, Rogers G, Friend J, et al. Long-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol 2001;119:1009-1019.
47. Kuzniarz M, Mitchell P, Cumming RG, Flood VM. Use of vitamin supplements and cataract: The Blue Mountains Eye Study. Am J Ophthalmol 2001;132:19-26.
48. Cumming RG, Mitchell P, Smith W. Diet and cataract: The Blue Mountains Eye Study. Ophthalmology 2000;107: 450-456.
49. Leske MC, Wu SY, Hyman L, Sperduto R, Underwood B, Chylack LT, et al. Biochemical factors in the lens opacities. Case-control study. The Lens Opacities Case-Control Study Group. Arch Ophthalmol 1995;113:1113-1119.
50. Mares-Perlman JA, Brady WE, Klein BE, Klein R, Haus GJ, Palta M, et al. Diet and nuclear lens opacities. Am J Epidemiol 1995;141:322-334.
51. Rautiainen S, Lindblad BE, Morgenstern R, Wolk A. Vitamin C supplements and the risk of age-related cataract: A population-based prospective cohort study in women. Am J Clin Nutr 2010;91:487-493.
52. Mathew MC, Ervin AM, Tao J, Davis RM. Antioxidant vitamin supplementation for preventing and slowing the progression of age-related cataract. Cochrane Database Syst Rev 2012;6:CD004567.
53. Hiller R, Sperduto RD, Podgor MJ, Wilson PW, Ferris 3rd FL, Colton T, et al. Cigarette smoking and the risk of development of lens opacities. The Framingham studies. Arch Ophthalmol 1997;115:1113-1118.
54. Klein BE, Klein R, Linton KL, Franke T. Cigarette smoking and lens opacities: The Beaver Dam Eye Study. Am J Prevent Med 1993;9:27-30.
55. West S, Munoz B, Emmett EA, Taylor HR. Cigarette smoking and risk of nuclear cataracts. Arch Ophthalmol 1989;107:1166-1169.
56. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bhala N, et al. Tobacco use in 3 billion individuals from 16 countries: An analysis of nationally representative crosssectional household surveys. Lancet 2012;380:668-679.
57. Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors, and cataract. The Blue Mountains Eye Study. Am J Epidemiol 1997;145:242-249.
58. Freeman EE, Munoz B, Schein OD, West SK. Hormone replacement therapy and lens opacities: The Salisbury Eye Evaluation project. Arch Ophthalmol 2001;119: 1687-1692.
59. Klein BE. Lens opacities in women in Beaver Dam, Wisconsin: Is there evidence of an effect of sex hormones? Trans Am Ophthalmol Soc 1993;91:517-544.
60. Klein BE, Klein R, Ritter LL. Is there evidence of an estrogen effect on age-related lens opacities? The Beaver Dam Eye Study. Arch Ophthalmol 1994;112:85-91.
61. Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E, Hales AM. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: The Blue Mountains Eye Study. Am J Epidemiol 2002;155:997-1006.
62. Kanthan GL, Wang JJ, Burlutsky G, Rochtchina E, Cumming RG, Mitchell P. Exogenous oestrogen exposure, female reproductive factors and the long-term incidence of cataract: The Blue Mountains Eye Study. Acta Ophthalmol 2010;88:773-778.
63. Worzala K, Hiller R, Sperduto RD, Mutalik K, Murabito JM, Moskowitz M, et al. Postmenopausal estrogen use, type of menopause, and lens opacities: The Framingham studies. Arch Intern Med 2001;161:1448-1454.
64. Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: The Beaver Dam Eye Study. Am J Ophthalmol 2000;130:322-326.
65. Defay R, Pinchinat S, Lumbroso S, Sultan C, Papoz L, Delcourt C. Relationships between hormonal status and cataract in french postmenopausal women: The POLA study. Ann Epidemiol 2003;13:638-644.
66. Lindblad BE, Hakansson N, Philipson B, Wolk A. Hormone replacement therapy in relation to risk of cataract extraction: A prospective study of women. Ophthalmology 2010;117:424-430.
67. Aina FO, Smeeth L, Hubbard R, Hurt LS, Fletcher AE. Hormone replacement therapy and cataract: A populationbased case-control study. Eye (Lond) 2006;20:417-422.
68. Wickham LA, Gao J, Toda I, Rocha EM, Ono M, Sullivan DA. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. Acta Ophthalmol Scand 2000;78:146-153.
69. Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA, Fauser BC. The effect of combined oral contraception on testosterone levels in healthy women: A systematic review and meta-analysis. Hum Reprod 2014; 20:76-105.
70. Sperduto RD, Hiller R. The prevalence of nuclear, cortical and posterior subcapsular lens opacities in a general population sample. Ophthalmology 1984;91:815-818.
71. Guyton AC. Textbook of medical physiology. Philadelphia: W.B. Saunders Company; 1991.
72. Ginsburg ES, Gao X, Shea BF, Barbieri RL. Half-life of estradiol in postmenopausal women. Gynecol Obstet Invest 1998;45:45-48.
73. Beebe-Dimmer J, Morgenstern H, Cetin K, Yee C, Bartoces M, Shahinian V, et al. Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. Ann Epidemiol 2011; 21:156-163.
74. Jensen EV. On the mechanism of estrogen action. Persp Biol Med 1962;6:47-59.
75. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 1986;320: 134-139.
76. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996;93: 5925-5930.
77. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277:1508-1510.
78. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138: 863-870.
79. O'Lone R, Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol 2004; 18:1859-1875.
80. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007;213:610-617.
81. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, et al. Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 2000;74:311-317.
82. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 2000;275: 5379-5387.
83. Kang L, Zhang X, Xie Y, Tu Y, Wang D, Liu Z, et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 2010;24:709-721.
84. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen signaling via estrogen receptor {beta}. J Biol Chem 2010; 285:39575-39579.
85. Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: A novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci 2008;29:116-123.
86. Bigsby RM, Cardenas H, Caperell-Grant A, Grubbs CJ. Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci USA 1999;96:9328-9332.
87. Kirker MR, Gallagher KM, Witt-Enderby PA, Davis VL. High affinity nuclear and nongenomic estradiol binding sites in the human and mouse lens. Exp Eye Res 2013;112: 1-9.
88. Ogueta SB, Schwartz SD, Yamashita CK, Farber DB. Estrogen receptor in the human eye: Influence of gender and age on gene expression. Invest Ophthalmol Vis Sci 1999;40:1906-1911.
89. Cascio C, Russo D, Drago G, Galizzi G, Passantino R, Guarneri R, et al. 17beta-estradiol synthesis in the adult male rat retina. Exp Eye Res 2007;85:166-172.
90. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125: 493-501.
91. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepulveda FV, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 1994;94:1690-1697.
92. Zhang JJ, Jacob TJ. Volume regulation in the bovine lens and cataract. The involvement of chloride channels. J Clin Invest 1996;97:971-978.
93. United Nations Department of Economic and Social Affairs PD. World population prospects: The 2010 revision, highlights and advance tables; 2011.
94. Fernandez Ballesteros R, Diez Nicolas J, Ruiz Torres A. Aging in Europe. Washington, DC: IOS Press; 1999.
95. Austad SN. Why women live longer than men: Sex differences in longevity. Gender Med 2006;3:79-92.
96. Arias E. United States life tables, 2004. National Vital Statistics Reports. Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System; 2007. Vol. 56, pp 1-39.
97. Candore G, Balistreri CR, Listi F, Grimaldi MP, Vasto S, Colonna-Romano G, et al. Immunogenetics, gender, and longevity. Ann NY Acad Sci 2006;1089:516-537.
98. Davis P, Graham P, Pearce N. Health expectancy in New Zealand, 1981-1991: Social variations and trends in a period of rapid social and economic change. J Epidemiol Commun Health 1999;53:519-527.
99. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: The challenges ahead. Lancet 2009;374: 1196-1208.
100. Clutton-Brock TH, Isvaran K. Sex differences in ageing in natural populations of vertebrates. Proc R Soc: Biol Sci 2007;274:3097-3104.
101. Barrett EL, Richardson DS. Sex differences in telomeres and lifespan. Aging Cell 2011;10:913-921.
102. Vitale C, Fini M, Speziale G, Chierchia S. Gender differences in the cardiovascular effects of sex hormones. Fundam Clin Pharmacol 2010;24:675-685.
103. Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular Aging in women: Is estrogen the fountain of youth? Front Physiol 2012;3:165.
104. Yanes LL, Reckelhoff JF. Postmenopausal hypertension. Am J Hypertension 2011;24:740-749.
105. Hamilton JB, Mestler GE. Mortality and survival: Comparison of eunuchs with intact men and women in a mentally retarded population. J Gerontol 1969;24:395-411.
106. Min KJ, Lee CK, Park HN. The lifespan of Korean eunuchs. Curr Biol 2012;22:R792-R793.
107. Hogervorst E,Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: A meta-analysis. Neuroscience 2000;101: 485-512.
108. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: Systematic review and meta-analysis. JAMA 2001;285:1489-1499.
109. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res 1997;778: 158-165.
110. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003;289:2651-2662.
111. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004;291:2947-2958.
112. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: Interaction with age. J Neurol Neurosurg Psychiatry 2005;76:103-105.
113. Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: The Women's Health Initiative 10 years on. Climacteric 2012;15:256-262.
114. Harman D. Aging: A theory based on free radical and radiation chemistry. J Gerontol 1956;11:298-300.
115. Cutler RG. Peroxide-producing potential of tissues: Inverse correlation with longevity of mammalian species. Proc Natl Acad Sci USA 1985;82:4798-4802.
116. Orr WC, Sohal RS. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science 1994;263:1128-1130.
117. Miquel J, Economos AC, Fleming J, Johnson Jr JE,. Mitochondrial role in cell aging. Exper Gerontol 1980;15: 575-591.
118. Borras C, Sastre J, Garcia-Sala D, Lloret A, Pallardo FV, Vina J. Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. Free Radic Biol Med 2003;34:546-552.
119. Kumar S, Lata K, Mukhopadhyay S, Mukherjee TK. Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: A perspective. Biochim Biophys Acta 2010;1800:1127-1135.
120. Yager JD, Chen JQ. Mitochondrial estrogen receptors-new insights into specific functions. Trends Endocrinol Metab 2007;18:89-91.
121. Stirone C, Duckles SP, Krause DN, Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005;68: 959-965.
122. Moosmann B, Behl C. The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999;96:8867-8872.
123. Green PS, Gordon K, Simpkins JW. Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol 1997;63:229-235.
124. Miller CP, Jirkovsky I, Hayhurst DA, Adelman SJ. In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein. Steroids 1996;61:305-308.
125. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995;214:847-855.
126. Alexaki VI, Charalampopoulos I, Kampa M, Vassalou H, Theodoropoulos P, Stathopoulos EN, et al. Estrogen exerts neuroprotective effects via membrane estrogen receptors and rapid Akt/NOS activation. FASEB J 2004;18: 1594-1596.
127. Rao AK, Ziegler YS, McLeod IX, Yates JR, Nardulli AM. Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells. J Mol Endocrinol 2009;43:251-261.
128. Axelrod N. Of telomeres and tumors. Nat Med 1996;2: 158-159.
129. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Gene 1996;18:173-179.
130. Meeker AK, Coffey DS. Telomerase: A promising marker of biological immortality of germ, stem, and cancer cells. A review. Biochem Biokhimiia 1997;62:1323-1331.
131. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol 2007;3:640-649.
132. Stindl R. Tying it all together: Telomeres, sexual size dimorphism and the gender gap in life expectancy. Med Hypotheses 2004;62:151-154.
133. Gardner M, Bann D, Wiley L, Cooper R, Hardy R, Nitsch D, et al. Gender and telomere length: Systematic review and meta-analysis. Exp Gerontol 2014;51:15-27.
134. Kyo S, Takakura M, Kanaya T, Zhuo W, Fujimoto K, Nishio Y, et al. Estrogen activates telomerase. Cancer Res 1999;59:5917-5921.
135. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exper Med 1997;185:273-280.
136. Bigsby RM, Valluri S, Lopez J, Mendonca MS, Caperell-Grant A, DesRosiers C, et al. Ovarian hormone modulation of radiation-induced cataractogenesis: Doseresponse studies. Invest Ophthalmol Vis Sci 2009;50: 3304-3310.
137. Davis VL, Chan CC, Schoen TJ, Couse JF, Chader GJ, Korach KS. An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci USA 2002;99:9427-9432.
138. Colitz CM, Davidson MG, McGahan GM. Telomerase activity in lens epithelial cells of normal and cataractous lenses. Exp Eye Res 1999;69:641-649.
139. Colitz CM, Whittington A, Carter R, Warren J. The effects of oxidative stress on telomerase activity and other stressrelated proteins in lens epithelial cells. Exp Eye Res 2004; 78:235-242.
140. Colitz CM, Sugimoto Y, Lu P, Barden CA, Thomas-Ahner J, Chandler HL. ERalpha increases expression and interacts with TERT in cataractous canine lens epithelial cells. Mol Vis 2009;15:2259-2267.
141. Michael R, Bron AJ. The ageing lens and cataract: A model of normal and pathological ageing. Philos Trans R Soc Lond Ser B, Biol Sci 2011;366:1278-1292.
142. Beebe DC, Holekamp NM, Shui YB. Oxidative damage and the prevention of age-related cataracts. Ophthalmic Res 2010;44:155-165.
143. Celojevic D, Petersen A, Karlsson JO, Behndig A, Zetterberg M. Effects of 17beta-estradiol on proliferation, cell viability and intracellular redox status in native human lens epithelial cells. Mol Vis 2011;17: 1987-1996.
144. Gajjar D, Patel D, Alapure B, Praveen MR, Patel A, Johar Sr K, et al. Rapid action of oestradiol against hydrogen peroxide-induced oxidative stress in cataractous lens epithelium: An in vitro study. Eye (Lond) 2009;23: 1456-1463.
145. Wang X, Simpkins JW, Dykens JA, Cammarata PR. Oxidative damage to human lens epithelial cells in culture: Estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci 2003;44: 2067-2075.
146. Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW. Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res 2004;78:861-871.
147. Cammarata PR, Flynn J, Gottipati S, Chu S, Dimitrijevich S, Younes M, et al. Differential expression and comparative subcellular localization of estrogen receptor beta isoforms in virally transformed and normal cultured human lens epithelial cells. Exp Eye Res 2005;81:165-175.
148. Flynn JM, Dimitrijevich SD, Younes M, Skliris G, Murphy LC, Cammarata PR. Role of wild-type estrogen receptor-beta in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells. Am J Physiol Endocrinol Metab 2008;295: E637-647.
149. Moor AN, Flynn JM, Gottipati S, Giblin FJ, Cammarata PR. 17beta-estradiol stimulates MAPK signaling pathway in human lens epithelial cell cultures preventing collapse of mitochondrial membrane potential during acute oxidative stress. Mitochondrion 2005;5: 235-247.
150. Flynn JM, Lannigan DA, Clark DE, Garner MH, Cammarata PR. RNA suppression of ERK2 leads to collapse of mitochondrial membrane potential with acute oxidative stress in human lens epithelial cells. Am J Physiol Endocrinol Metab 2008;294:E589-599.
151. Vina J, Borras C, Gambini J, Sastre J, Pallardo FV. Why females live longer than males? Importance of the upregulation of longevity-associated genes by oestrogenic compounds. FEBS Lett 2005;579:2541-2545.
152. Gottipati S, Cammarata PR. Mitochondrial superoxide dismutase activation with 17 beta-estradioltreated human lens epithelial cells. Mol Vis 2008;14: 898-905.
153. Pedram A, Razandi M, Wallace DC, Levin ER. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 2006;17:2125-2137.
154. Razmara A, Duckles SP, Krause DN, Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 2007;1176:71-81.
155. Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K, et al. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res 2003;93: 170-177.
156. Borras C, Gambini J, Gomez-Cabrera MC, Sastre J, Pallardo FV, Mann GE, et al. 17beta-oestradiol up-regulates longevity-related, antioxidant enzyme expression via the ERK1 and ERK2[MAPK]/NFkappaB cascade. Aging Cell 2005;4:113-118.
157. Giddabasappa A, Bauler M, Yepuru M, Chaum E, Dalton JT, Eswaraka J. 17-beta estradiol protects ARPE-19 cells from oxidative stress through estrogen receptorbeta. Invest Ophthalmol Vis Sci 2010;51:5278-5287.
158. Razmara A, Sunday L, Stirone C, Wang XB, Krause DN, Duckles SP, et al. Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells. J Pharmacol Exp Ther 2008;325:782-790.
159. Chen KC, Zhou Y, Xing K, Krysan K, Lou MF. Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: The redox signaling. Exp Eye Res 2004;78:1057-1067.
160. Santen RJ, Allred DC. The estrogen paradox. Nat Clin Practice: Endocrinol Metab 2007;3:496-497.
161. Zetterberg M, Petersen A, Karlsson J-O, Sundelin K. Proliferation of cultured lens epithelial cells and association with possible risk factors for posterior capsular opacification. Acta Ophthalmol 2010;88:S246.
162. Ninn-Pedersen K, Bauer B. Cataract patients in a defined Swedish population 1986-1990. VI. YAG laser capsulotomies in relation to preoperative and surgical conditions. Acta Ophthalmol Scand 1997;75:551-557.